Related Experiment Video
Updated: May 23, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
New developments in the management of diffuse large B-cell lymphoma.
1Mayo Clinic, Rochester, MN 55905, USA. habermann.thomas@mayo.edu
Hematology (Amsterdam, Netherlands)
|April 18, 2012
Summary
Diffuse large B-cell lymphoma (DLBCL) treatment has advanced with immunochemotherapy like R-CHOP and autologous stem cell transplantation. Ongoing research explores novel regimens and targeted therapies for improved outcomes in DLBCL patients.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Diffuse large B-cell lymphoma (DLBCL) is the most common adult non-Hodgkin lymphoma.
- R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, prednisone) is the current standard immunochemotherapy for DLBCL.
- Treatment duration and specific regimens like R-ACVBP have been evaluated in various trials.
Purpose of the Study:
- To review the evolution of DLBCL treatment strategies.
- To evaluate the efficacy of immunochemotherapy and autologous stem cell transplantation (ASCT).
- To discuss emerging therapies and future directions in DLBCL management.
Main Methods:
- Review of past and ongoing clinical trials in DLBCL.
- Analysis of data from microarray and hypersequencing studies.
- Evaluation of standard-of-care treatments and novel therapeutic approaches.
Main Results:
- R-CHOP and ASCT are established treatments for DLBCL.
- New regimens like EPOCH-R and maintenance therapies are under investigation.
- Targeted therapies, including lenalidomide and Bruton's tyrosine kinase inhibitors, show promise.
Conclusions:
- Immunochemotherapy and ASCT have significantly improved DLBCL outcomes.
- Targeted therapies and novel agents are transforming DLBCL treatment.
- Continued research into new pathways and targets is crucial for advancing DLBCL care.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...